It’s not uncommon for businesses that have hit tough times to undergo a rebrand–and embattled Valeant is thinking about undergoing one of its own.
The company could change its name to help repair its reputation, Valeant boardmember and activist investor Bill Ackman told CNBC Wednesday. One option? Taking on the name of its top business, eyecare giant Bausch & Lomb, the news service’s sources said. Several other names are on the table, though, and the company hasn’t made a final decision on whether it’ll go through with the moniker swap.
Valeant’s reputation could certainly use a boost after the last year-plus, over which it’s faced political pricing pushback and channel-stuffing allegations. The company has already made moves to break with its past, bringing in new CEO Joseph Papa to replace M&A-happy J. Michael Pearson–and, of course, bringing Ackman on board.
But with several investigations into the company underway–and reports saying U.S. prosecutors are building a fraud case against Valeant–the Canadian drugmaker hasn’t been able to put as much of its past behind it as it would have liked.
If Valeant does make a name change, it won’t be the first pharma in recent memory to do so. Last year, after Actavis swallowed Allergan–a company it stole away from hostile suitor Valeant–the generics powerhouse decided to take on the name and identity of its brands-focused acquisition. Since then, the combined Allergan has completed a transformation, selling off its Actavis copycat business to Teva in a $40-billion-plus transaction this summer.
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
